Therapeutic equivalence of Levodopa products -in vitro studies-

dc.contributor.advisorHikal, Ahmed H.
dc.contributor.committeeMemberZlatkis, Albert
dc.contributor.committeeMemberClay, Michael M.
dc.contributor.committeeMemberGeorge, M. George
dc.creatorEl-Yazigi, Adnan
dc.description.abstractThe dissolution rates of eight products containing Levodopa in three strengths and made by two different manufacturers have been determined using a continuous flow dissolution apparatus. There was no significant difference between a 100 mg. tablet of one manufacturer and a 100 mg. capsule of the other manufacturer. Significant difference was observed in the 250 mg. capsules made by the different manufacturers. At 250 mg. strength the dissolution of the capsule differed from that of the tablet of the same manufacturer. There was no significant variation in 500 mg. tablets or capsules made by different manufacturers. The unit-to-unit variation within the same product was varied from one product to the next. The change in strength was found to influence dissolution rate significantly. All products studied passed the U.S.P. XVIII content uniformity test.
dc.description.departmentPharmacy, College of
dc.format.digitalOriginreformatted digital
dc.rightsThis item is protected by copyright but is made available here under a claim of fair use (17 U.S.C. Section 107) for non-profit research and educational purposes. Users of this work assume the responsibility for determining copyright status prior to reusing, publishing, or reproducing this item for purposes other than what is allowed by fair use or other copyright exemptions. Any reuse of this item in excess of fair use or other copyright exemptions requires express permission of the copyright holder.
dc.titleTherapeutic equivalence of Levodopa products -in vitro studies-
dc.type.genreThesis of Pharmacy, College of of Houston of Science


Original bundle

Now showing 1 - 1 of 1
Thumbnail Image
1.57 MB
Adobe Portable Document Format